Clinical evaluation of the first domestically produced generic isosulfan blue injection in sentinel lymph node biopsy for early breast cancer in China: a multicenter, single-arm, open validation trial (CSBrS-024)
Main Authors: | Fengjiang Qu, Di Wu, Yunjiang Liu, Wei Gao, Shu Wang, Siyuan Wang, Feng Jin, Bo Chen, Jian Huang, Shanshan Sun, Zhimin Fan, Chinese Society of Breast Surgery, Yanjie Yin, Xiuyuan Hao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2022-07-01
|
Series: | Chinese Medical Journal |
Online Access: | http://journals.lww.com/10.1097/CM9.0000000000002309 |
Similar Items
-
Clinical practice guidelines for the diagnosis and treatment of inflammatory breast cancer: Chinese Society of Breast Surgery (CSBrS) Practice Guidelines 2022
by: Li Ma, et al.
Published: (2023-08-01) -
Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015)
by: Yuanjia Cheng, et al.
Published: (2022-10-01) -
The outcome of neoadjuvant chemotherapy and the current trend of surgical treatment in young women with breast cancer: A multicenter real-world study (CSBrS-012)
by: Yijun Li, et al.
Published: (2023-02-01) -
Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012)
by: Heyan Chen, et al.
Published: (2023-02-01) -
Survival in Breast Cancer Patients with Bone Metastasis: A Multicenter Real-World Study on the Prognostic Impact of Intensive Postoperative Bone Scan after Initial Diagnosis of Breast Cancer (CSBrS-023)
by: Liu Yang, et al.
Published: (2022-11-01)